Global Health Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing a Global Health target price for 2027 should start with where the stock sits today. At Rs 1,312.70 on 9 October 2026, it is 15.0% below its 52-week high of Rs 1,544.00 and 37.3% above its 52-week low of Rs 956.00. That range spans 62% from low to high, so the entry point matters as much as the Global Health price forecast itself.

This article builds the Global Health share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 1,375 base case and the Rs 1,669 bull case were reached, along with a downside risk level of Rs 1,021.

Click Here – Get Free Investment Predictions

Global Health Stock Analysis: Company Overview and Key Stats

Global Health (NSE: MEDANTA) has a market capitalisation of Rs 34,310 crore. In FY26 it reported revenue of Rs 4,509 crore and net profit of Rs 554.07 crore. The table collects the figures the Global Health share price target is built on.

Metric	Value
Company	Global Health
NSE Ticker	MEDANTA
CMP (9 October 2026)	Rs 1,312.70
52-Week High	Rs 1,544.00
52-Week Low	Rs 956.00
Market Cap	Rs 34,310 crore
PE Ratio (TTM)	62.13
Industry PE	62.79
Price to Book	8.66
Return on Equity	14.05%
Debt to Equity	0.30
EPS (TTM)	Rs 20.54
Dividend Yield	0.04%
12-Month Base Target	Rs 1,375
Bull Case	Rs 1,669
Downside Risk Level (not a target)	Rs 1,021

Why Is Global Health Share Price Target Set at Rs 1,375 for 2027?

The base-case Global Health stock target of Rs 1,375 applies a PE multiple of 62.13 to a forward EPS estimate of Rs 22.13. That EPS assumes 7.7% yearly growth, the pace from FY24 to FY26, and puts the target 4.7% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Global Health Target Price: Five Years of Results

Global Health grew revenue from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew faster, from Rs 196.20 crore to Rs 554.07 crore (29.6% a year), which shows margin gains did part of the work and not just higher sales.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	2,205.82	196.20	7.77	0.00
FY23	2,759.16	326.08	12.57	0.00
FY24	3,349.78	478.06	17.80	0.00
FY25	3,771.29	481.32	17.92	0.00
FY26	4,508.86	554.07	20.66	0.50

FY26 revenue growth was 19.6%, close to the four-year average of 19.6%, and net profit moved up 15.1%. EPS rose from Rs 17.80 in FY24 to Rs 20.66 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Global Health converted 12.3% of FY26 revenue into net profit, against 12.8% in FY25, within a five-year range of 8.9% to 14.3%. EBITDA margin was 22.5% in FY26 versus 24.0% in FY25.

In the June 2026 quarter, revenue was Rs 1,326 crore, up 26.1% from the same quarter a year earlier, while net profit of Rs 157.25 crore was down 1.1%. EBITDA came in at Rs 308.92 crore, up 15.7% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.30, and shareholders' equity grew from Rs 1,616 crore in FY22 to Rs 3,984 crore in FY26. Operating cash flow in FY26 was Rs 714.39 crore against capital expenditure of Rs 838.19 crore, leaving negative free cash flow of Rs 123.80 crore. In FY25 free cash flow was Rs 107.21 crore, so cash generation has not been steady year to year.

Valuation Check for the Global Health Stock Target: PE, Price to Book and ROE

At a PE of 62.13 against an industry PE of 62.79, Global Health trades in line with its industry. Price to book is 8.66 on a book value of Rs 147.34 per share, and return on equity is 14.05%. A PE of 62.13 equals an earnings yield of 1.6%, and the FY26 dividend of Rs 0.50 per share gives a yield of 0.04%.

Shareholding Pattern and Institutional Holding

Promoters held 33.00% of Global Health in June 2026, and promoter holding has stayed near 33.00% since June 2025. Foreign institutional investors (FII) held 9.46% and domestic institutions (DII) held 16.89%, which puts total institutional holding at 26.35%. FII holding fell from 11.54% in June 2025 to 9.46% in June 2026. Public shareholders own the remaining 40.65%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Global Health Share Price Targets for the Short Term and 12 Months

Short Term Global Health Stock Target Levels: Technical Setup

At Rs 1,312.70 on 9 October 2026, Global Health trades below its 50-day simple moving average of Rs 1,426.78 and above its 200-day exponential moving average of Rs 1,298.17. The 14-day RSI reads 21.5, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 1,426.78 (50-day simple moving average) and the nearest support is Rs 1,298.17 (200-day exponential moving average). A sustained move above Rs 1,426.78 would improve the short-term setup, while a close below Rs 1,298.17 would shift attention to the next support.

12 Month Global Health Target Price for 2027

The 12-month target for Global Health is Rs 1,375: forward EPS of Rs 22.13 at a PE of 62.13. That is 4.7% above Rs 1,312.70. It would still leave the stock 10.9% below its 52-week high of Rs 1,544.00. The upside in the base case is thin, so the thesis here leans on the bull case and on patience.

How EPS Growth and PE Multiple Change the Global Health Target Price

EPS Growth	PE 49.70	PE 62.13	PE 71.45
0.0% (EPS Rs 20.54)	Rs 1,021	Rs 1,276	Rs 1,468
7.7% (EPS Rs 22.13)	Rs 1,100	Rs 1,375	Rs 1,581
13.7% (EPS Rs 23.36)	Rs 1,161	Rs 1,451	Rs 1,669

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Global Health price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Global Health Stock Target in 2027

Bull Case Rs 1,669

The bull case Global Health price target needs EPS growth of 13.7%, which lifts forward EPS to Rs 23.36, and a PE multiple that rises 15% to 71.45. That gives Rs 1,669, 27.1% above the current price and above the 52-week high of Rs 1,544.00, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 1,021

The downside risk level is not a target. It assumes EPS stays flat at Rs 20.54 and the PE falls 20% to 49.70. That gives Rs 1,021, 22.2% below the current price and above the 52-week low of Rs 956.00.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	13.7%	71.45	Rs 1,669	+27.1%
Base Case	7.7%	62.13	Rs 1,375	+4.7%
Downside Risk	0.0%	49.70	Rs 1,021	-22.2%

Key Risks to the Global Health Target Price for 2027

Growth Slowdown Risk for the Global Health Price Target

Revenue in the June 2026 quarter was up 26.1% year on year, and FY26 revenue growth was 19.6%. If growth slows from here, the EPS estimate behind the Global Health stock target will need revising.

Liquidity and Size Risk

Global Health has a market capitalisation of Rs 34,310 crore. Institutional holding is 26.35%, and promoters hold 33.00%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 12.3% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 62.13 versus an industry PE of 62.79, a de-rating toward the downside-risk PE of 49.70 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 15.0% below its 52-week high, with an RSI of 21.5 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Global Health

Start with the live price and volume. Any Global Health share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 1,312.70 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Global Health's PE, ROE, debt and shareholding in one place.

Check Global Health fundamentals on the Univest Screener

Then compare the three Global Health target price scenarios with your own view. If you expect EPS growth below 7.7%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Global Health live price and get daily stock recommendations.

Conclusion

The Global Health share price target for 2027 is Rs 1,375 in the base case, with Rs 1,669 as the bull case. The support for that view is arithmetic you can check: EPS grew 7.7% a year over FY24 to FY26, and the stock trades at a PE of 62.13. The risks are equally concrete, including a stock that sits 15.0% below its 52-week high and a downside scenario that cuts the price 22% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Global Health Share Price Target 2027

What is the Global Health share price target for 2027?

Ans. The base-case Global Health share price target for 2027 is Rs 1,375, with Rs 1,669 as the bull case. The downside risk level, which is not a target, is Rs 1,021. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Global Health share price today?

Ans. As of 9 October 2026, 3:30 PM IST, Global Health trades at Rs 1,312.70, up 2.84% on the day. The 52-week range is Rs 956.00 to Rs 1,544.00.

Is Global Health a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 7.7% a year over FY24 to FY26, but the stock is 15.0% below its 52-week high. Whether Global Health fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Global Health shares?

Ans. The bull case target is Rs 1,669, which assumes 13.7% EPS growth and a PE of 71.45. The downside risk level is Rs 1,021, which assumes flat EPS and a PE of 49.70. It marks a risk, not a target.

What are the main risks to the Global Health price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 34,310 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Global Health and how does it compare with the industry?

Ans. The PE ratio of Global Health is 62.13 against an industry PE of 62.79. Price to book is 8.66 and return on equity is 14.05%. The base case in the Global Health price target holds this PE constant.

Who owns Global Health, and what is the promoter holding?

Ans. Promoters held 33.00% of Global Health in June 2026. FII held 9.46%, DII held 16.89% and the public held 40.65%.

What were Global Health's latest quarterly results?

Ans. In the June 2026 quarter, Global Health reported revenue of Rs 1,326 crore (up 26.1% year on year) and net profit of Rs 157.25 crore (down 1.1%).